London, UK, and Redwood City, California, 20 March 2006 – Inpharmatica Ltd, today announces a collaboration agreement with Ingenuity Systems, Inc, Redwood City, California. Under the terms of the agreement, the two companies will work together to bring their customers the benefits of using in tandem two advanced and independently-developed drug discovery tools.
A major benefit of the agreement is that researchers working with the popular Affymetrix GeneChips will be able access world-class knowledge-bases that cover all aspects of research from initial probe assignment to details of the protein network.
The two products are Inpharmatica’s probe to protein assignment module; Blu-ChipT and Ingenuity’s Pathway Analysis (IPA). Blu-Chip and IPA are different types of solutions designed to facilitate work in a number of research areas.
Inpharmatica’s Blu-ChipT offers biologists an essential resource for resolving probe to protein assignments, maximizing the value of GeneChip® experiments. With Blu-Chip, researchers access a powerful knowledgebase of preferred and alternative assignments. An intuitive interface enables them to resolve ambiguity and build more valued judgements. Blu-Chip is particularly effective at distinguishing splice variants and isoforms, as well as providing clear indications of intronic location.
IPA is a web-delivered software application that enables researchers to model, analyze and understand the complex biological systems at the core of life science research. IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports analysis of all high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.
“Ingenuity’s IPA software has garnered favorable opinions throughout the research community, and we look forward to an effective partnership with the company,” said John Lisle, CEO of Inpharmatica. “This is Inpharmatica’s first collaboration of this kind and we believe that it will prove a huge success as it enables researchers to move seamlessly through two key steps of analysis – probe assignment and protein network analysis – thus simplifying workflows and accelerating discoveries.”
“Inpharmatica is an established player in the field of drug discovery technologies and services and we are excited to be working with them,” said Tuan Nguyen, Vice President of Partner and Professional Services, of Ingenuity Systems. “The synergy provided by offering Blu-Chip and IPA together will bring benefits to our users in the research community and to the two companies themselves – a win-win for all concerned.”
About Ingenuity Systems® (www.ingenuity.com)
Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotech companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan.
Founded in 1998, Inpharmatica uses predictive informatics in genomics, medicinal chemistry and ADME to improve the speed and productivity of drug discovery. The company employs around 90 professionals at its UK locations in London and Cambridge, with business development in North America and Japan. Inpharmatica’s unique proprietary technologies and skills are utilised in major discovery laboratories worldwide including Serono, Pfizer, GSK, Novartis, sanofi-aventis, P&G Pharmaceuticals, and Daiichi.
Inpharmatica is unique in offering discovery technologies and services which span the full breadth of research from gene through to candidate selection: the core elements are fully integrated, enabling customers to access the full end-to-end technologies, or individual components and services as required.